The University at Buffalo (UB) has announced that a new Trial Innovation Network (TIN) is creating a path for investigators to perform multi-site studies in better and less expensive ways.

The TIN is a joint effort within the clinical and translational science award (CTSA) programme designed to ramp up the translation of new breakthroughs into life-saving approaches used in clinical settings.

UB Clinical Research Office director Sanjay Sethi said: “The goals of TIN and the University at Buffalo Clinical and Translational Science Institute are well aligned.

“These include to develop and implement innovative, collaborative solutions intended to transform clinical and translational research, especially multi-site clinical trials, and to promote the integration of special and underserved populations in translational research across the lifespan.” ​

A national laboratory created by TIN helps medical investigators to collaborate on research.

The TIN is made up of the CTSA programme hubs, the trial innovation centre (TIC), and the recruitment innovation centre (RIC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Researchers at CTSA institutions across the country will be able to organise research processes through the network which offers a single Institutional Review Board for multi-centre clinical studies.

Using the network, investigators will be able to better focus on conducting evidence-based research and recruit participating patients.

UB CTSI TIN liaison point of contact clinical recruitment coordinator Briana Getman says that TIN is beneficial to investigators in two key ways.

The first is that, UB teams planning to submit proposals for National Institutes of Health (NIH) funding can request a TIN consultation for their own multi-site trials, receiving feedback and guidance on study design, recruitment and feasibility.

Secondly, the investigators can be selected as a site investigator when other CTSA hubs are looking for sites to conduct their multi-centre trials.

Sethi added: “If a UB investigator has a multi-site proposal that is in the planning phase, the TIN can provide a proposal review that can greatly enhance the quality of the proposal and increase its probability of funding.

“If the local investigator has a funded proposal, the TIN can be used to find sites to conduct the study within the CTSA.”

Until now, three UB teams have been confirmed as primary investigators through the TIN system.